Sarah L. Mott

Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy.

A. Kibel, M. Preston, G. Steele, 2023, Urologic oncology.

Impact of bladder cancer family history on the prognosis of patients with non-muscle invasive bladder cancer treated with Bacillus Calmette-Guerin (BCG)

Mohamad A. Moussa, Sarah L. Mott, Michael A. O’Donnell, 2024, Expert opinion on pharmacotherapy.

Prognostic role of the neutrophil/lymphocyte ratio in high-risk BCG-naïve non-muscle-invasive bladder cancer treated with intravesical gemcitabine/docetaxel.

M. Chakra, Sarah L. Mott, Michael A. O’Donnell, 2024, BJU international.

A Multinational, Multi-Institutional Study Assessing the Impact of Diabetes Mellitus on the Prognosis of Patients with Non-Muscle Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin.

Mohamad A. Moussa, Sarah L. Mott, Michael A. O’Donnell, 2024, Nutrition and cancer.

Sequential Endoluminal Gemcitabine and Cabazitaxel with Intravenous Pembrolizumab as a Bladder-Preserving Strategy for Docetaxel-Unresponsive Non-Muscle Invasive Urothelial Carcinoma Following Transurethral Resection of Bladder Tumor

Ryan L. Steinberg, Ian M. McElree, Sarah L. Mott, 2024, Cancers.

Responding to distress in cancer care: Increasing access to psycho oncology services through integrated collaborative care

Martin Kivlighan, Arwa Aburizik, Nathen A Spitz, 2023, Psycho-oncology.